Thomas C. Seoh

Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury

Arbios Systems, Inc. engages in the development, manufacture, and marketing of liver assist therapies for medical treatment of liver failure. The company was founded by Achilles A. Demetriou and Jacek Rozga in February 1999 and is headquartered in Allendale, NJ.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

NexGen Medical Systems, Inc. develops medical devices that enhance the safety and effectiveness of interventional procedures in patients with debilitating neurological and cardiovascular diseases. The firm focuses on commercializing an integrated medical device product line for removal of blood clots from head, neck, and peripheral vessels. The company was founded by Richard E. Latchaw, John Kucharczyk and George T. Gillies and is headquartered in Wayzata, MN.